Literature DB >> 11761260

Viral latency--the papillomavirus model.

T R Broker1, G Jin, A Croom-Rivers, S M Bragg, M Richardson, L T Chow, S H Vermund, R D Alvarez, P G Pappas, K E Squires, C J Hoesley.   

Abstract

To investigate the prevalence and the natural history of human papillomavirus infections, we monitored HPV DNA shedding as a consequence of immunosuppression, with the expectation that latent viral infections would reactivate and become detectable. The study populations consisted of women who were in end-stage renal failure, those who ultimately received kidney transplantations, and those who had HIV/AIDS with various degrees of immune depression at entry. For each woman, cervico-vaginal lavage to sample viral shedding from the lower genital tract was performed at approximately six month intervals, and the cohorts have been followed since 1996. Nested polymerase chain reaction amplification of papillomavirus DNA using novel pairs of primers was followed by diagnostic restriction endonuclease cleavage or by DNA sequencing. This strategy is particularly capable of identifying single and multiple infections and determining the genotypes of any viruses present. Of the 225 women in the HIV cohort, 177 (79%) were HPV-positive and 111 (49%) shed from two up to eight different HPV types over the course of the survey. Thirty-five different mucosotropic HPV types, virtually all that have ever been described worldwide, were isolated from these 225 women, and nine additional new (provisional) types were discovered. As is always the case, HPV-6 was very common. However, all the other frequently detected HPV types (45, 52, 53, 54, 58, 74) were more prevalent than the types typically reported forthe general population (HPV-11, 16, 18, 31, 33, 35). Notably, the 14 members of the A3 phylogenetic subgroup (HPV-61, 62, 72, 81, 83, 84, and all the new types) were by far the most frequently observed viral types in the AIDS cohort. The HPV prevalence in the cohorts of kidney transplantation candidates and recipients was only slightly lower than that in the AIDS cohort. We conclude that HPV infections are extraordinarily common and are normally held in a sub-clinical state by functional immune systems, but can be reactivated by immunosuppressive conditions. The question of how so many distinct types persist in the human population and can be repeatedly isolated from specimens collected around the world raises complex issues concerning the nature of viral transmission, reproduction, shedding, and mutational drift. These molecular epidemiological observations signal the likelihood that HPV is part of the commensal microflora of human epithelia. Their prevalence elicits a caution that latent HPV DNA may be present in primary human epithelial tissues.

Entities:  

Mesh:

Year:  2001        PMID: 11761260

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  20 in total

1.  Management of adult recurrent respiratory papillomatosis with oral acyclovir following micro laryngeal surgery: a case series.

Authors:  Jagdish Chaturvedi; V Sreenivas; V Hemanth; R Nandakumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-06

Review 2.  The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

Authors:  Hugo De Vuyst; Laia Alemany; Charles Lacey; Carla J Chibwesha; Vikrant Sahasrabuddhe; Cecily Banura; Lynette Denny; Groesbeck P Parham
Journal:  Vaccine       Date:  2013-12-29       Impact factor: 3.641

3.  Extralaryngeal HPV infections in male patients with adult-onset laryngeal papillomatosis.

Authors:  Leena-Maija Aaltonen; Suvi Cajanus; Leif Bäck; Pekka Nieminen; Jorma Paavonen; Annamari Ranki
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-08-24       Impact factor: 2.503

Review 4.  DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.

Authors:  Nicholas D Weber; Martine Aubert; Chung H Dang; Daniel Stone; Keith R Jerome
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

5.  Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe.

Authors:  Rebecca G Nowak; Patti E Gravitt; Charles S Morrison; Stephen J Gange; Cynthia Kwok; Amy E Oliver; Roslyn Howard; Barbara Van der Pol; Robert A Salata; Nancy S Padian; Tsungai Chipato; Marshall Munjoma; David D Celentano
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

6.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

7.  Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Togami; Yuko Sasajima; Takahiro Kasamatsu; Rie Oda-Otomo; Satoshi Okada; Mitsuya Ishikawa; Shun-ichi Ikeda; Tomoyasu Kato; Hitoshi Tsuda
Journal:  Pathol Oncol Res       Date:  2014-11-05       Impact factor: 3.201

Review 8.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

9.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

10.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.